Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age

By de Kleijn E.D.   de Groot R.   Labadie J.   Lafeber A.B.   van den Dobbelsteen G.   van Alphen L.   van Dijken H.   Kuipers B.   van Omme G.-W.G.-W.   Wala M.   Juttmann R.   Rumke H.C.  

Vaccine, Vol. 18, Iss. 15, 2000-02 ,pp. : 1456-1466

Elsevier

Access to resources Recommend Favorite

Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine

By Martin S.L.   Borrow R.   van der Ley P.   Dawson M.   Fox A.J.   Cartwright K.A.V.  

Vaccine, Vol. 18, Iss. 23, 2000-05 ,pp. : 2476-2481

Elsevier

Access to resources Recommend Favorite

Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine

By Peeters C.C.A.M.   Rumke H.C.   Sundermann L.C.   van der Voort E.M.R.   Meulenbelt J.   Schuller M.   Kuipers A.J.   van der Ley P.   Poolman J.T.  

Vaccine, Vol. 14, Iss. 10, 1996-07 ,pp. : 1009-1015

Elsevier

Access to resources Recommend Favorite

Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys

By Rouppe van der Voort E.   Schuller M.   Holst J.   de Vries P.   van der Ley P.   van den Dobbelsteen G.   Poolman J.  

Vaccine, Vol. 18, Iss. 14, 2000-02 ,pp. : 1334-1343

Elsevier

Access to resources Recommend Favorite

Immunogenicity and safety of monovalent P1.7 h ,4 meningococcal outer membrane vesicle vaccine in toddlers: comparison of two vaccination schedules and two vaccine formulations

By de Kleijn E.D.   de Groot R.   Lafeber A.B.   Labadie J.   van Limpt K.C.J.P.   Visser J.   Berbers G.A.M.   van Alphen L.   Rumke H.C.  

Vaccine, Vol. 19, Iss. 9, 2000-12 ,pp. : 1141-1148

Elsevier

Access to resources Recommend Favorite